Cloud-Clone antibody used in microgel therapy study for heart attack repair

Researchers at Zhejiang University developed a core-shell microgel system that recruits and strengthens regulatory T cells after myocardial infarction, aiming to reduce inflammation and improve cardiac repair. The study used a biotin-labeled Cloud-Clone anti-CCL17 antibody as a key component of the platform.

Why it matters: - Myocardial infarction can leave heart tissue stuck in a chronic inflammatory state that slows repair. - The Zhejiang University approach targets two problems at once: weak regulatory T-cell recruitment and poor T-cell function. - The platform could point to a new immunomodulatory strategy for post-infarction cardiac repair.

What happened: - Zhejiang University researchers published work on CCL17-neutralizing and esterase-responsive core-shell microgels for endogenous Treg recruitment and functional enhancement in myocardial infarction. - The study used a biotin-labeled anti-CCL17 antibody from Cloud-Clone, catalog number LAB571Mu71, as a building block in the therapeutic construct. - The microgel system is called Ab/HAPA@C-S MGs. - The work was framed as a sequential strategy to recruit endogenous Tregs and then boost their suppressive capacity.

The details: - The outer shell carries anti-CCL17 neutralizing antibodies on the microgel surface. - The shell is designed to bind excess CCL17 and remove a chemokine barrier that limits Treg homing. - In vitro Transwell assays showed surface-tethered anti-CCL17 antibodies improved Treg migration under inflammatory conditions. - The inner core encapsulates HAPA, a prodrug precursor. - Infarct tissue esterase activity drives HAPA hydrolysis and releases propionic acid. - Propionic acid strengthens Treg suppressive activity, increases Foxp3 expression and promotes macrophage polarization toward the reparative M2 phenotype. - The shell and core functions are designed to work in tandem with aligned release kinetics. - ELISA results showed the antibody on Ab/HAPA@C-S MGs neutralized CCL17 in culture medium. - Under esterase-mimicking conditions, the microgels sustained continuous propionic acid release. - Tregs treated with the system showed elevated Foxp3 and increased IL-10 secretion. - The platform also increased macrophage conversion to the M2 reparative phenotype. - In mouse myocardial-infarction models, the microgels produced early immunomodulatory effects through a recruitment-then-enhancement sequence. - Transcriptomic analysis showed the therapy remodeled metabolic networks in infarct-infiltrating immune cells and shifted responses from pro-inflammatory to pro-reparative profiles.

Between the lines: - The study combines a neutralizing antibody and a prodrug-loaded biomaterial to coordinate spatial and temporal immune control. - The design suggests that post-infarction repair may require both chemokine blockade and functional immune-cell reprogramming, not just one or the other. - Cloud-Clone's antibody was used as a research reagent in a higher-complexity biomaterial system, underscoring how reagent quality can affect translational biomaterials work. - The company notes that its antibody products are backed by ISO 9001 and ISO 13485 certifications and a three-level quality-control framework.

What's next: - The in-vivo results suggest the platform could support future cardiac immunotherapy research. - Further development would likely focus on validating the approach in broader preclinical settings and moving toward translational study design. - The study positions spatiotemporally coordinated immune modulation as a possible template for other inflammatory diseases.

The bottom line: - Zhejiang University's microgel platform shows how a CCL17-neutralizing antibody and metabolite release can be combined to recruit Tregs, enhance their function and improve the post-heart-attack immune environment.